Method for producing rabbit plague vaccine with cell line and its product

Abstract

The invention provides a method for producing RHD (rabbit haemorrhagic disease) virus and vaccine by use of common easy-to-culture cell lines such as RK13, ST, VeroE6, BHK-21, PK-15, IBRS-2 and the like. The method comprises the following steps of: inoculating the RHD virus and adsorbing; adding an incubation agent and performing cell incubation; culturing cells with a cell maintenance medium to obtain RHD virus seeds for production; inoculating the RHD virus seeds and adsorbing; adding an incubation agent and performing cell incubation; re-adding a cell maintenance medium and culturing cells to obtain the RHD virus for vaccine preparation; adding an inactivator for inactivation; and then adding a veterinary-pharmaceutically acceptable vaccine adjuvant to obtain a finished product of the RHD vaccine. According to the method, the cell line for virus culture is a mature commercial cell line, the production technology is simple and stable, the operation is easy, the virus content is high, the inter-batch difference is little, the quality is easy to control, and the output and quality of the vaccine can be obviously improved. Through the invention, the produced RHD vaccine has high safety and high immunity, and realizes a complete immune protection effect against the RHD virulent attack.

Description

technical field [0001] The invention relates to a method for producing a rabbit plague vaccine by using a cell line and a product thereof, belonging to the field of veterinary vaccines. Background technique [0002] Rabbit viral hemorrhagic disease (rabbitheamorrhagicdisease, RHD) is a new viral disease first discovered and reported by my country in 1984. Because of its acute onset, rapid spread, high morbidity and mortality, it is also commonly known as "rabbit plague". infectious disease. At present, it is popular in all provinces (cities) in China. Italy, Germany, France, the former Czechoslovakia, the former Soviet Union, Spain, Mexico, North Korea and Japan also occurred. Causing huge economic losses to the rabbit industry all over the world, the International Veterinary Bureau listed the disease as a Class B infectious disease, and my country's Ministry of Agriculture Order No. 96 promulgated it as a Class II disease. The emergence of RHD is relatively sudden and t...

AI Technical Summary

Problems solved by technology

For example, Chinese patent CN88108859.5 discloses a method for cultivating RHD virus with diseased rabbit liver tissue and producing rabbit plague vaccine, but in the preparation process of the vaccine, the dead rabbit visceral tissue infected with RHDV must be used as raw material for the preparation of The supply of non-immunized rabbits with tissue inactivated vaccines is very unstable, resulting in the continuous increase in the cost of traditional tissue inactivated vaccines. In addition, tissue inactivated vaccines have potential risks of spreading virulence, large batch-to-batch differences, and low yields. shortcoming

[0004] In recent years, with the rise of industries such as rabbit products and the increase in demand for rabbits such as other animal vaccines, the market demand for rabbit viral hemorrhagic disease vaccines has increased a lot, but non-immune vaccines used to prepare tissue inactivated vaccines The supply of rabbits is very unstable, which causes the cost of traditional tissue-inactivated vaccines to increase continuously. In addition, tissue-inactivated vaccines have various shortcomings such as the potential risk of spreading virulence, large batch-to-batch differences, and low yields. Wide application is subject to certain limitations

Images